• Akeso announced published Phase II results for perioperative ivonescimab in resectable non-small cell lung cancer in Nature Medicine.
• Ivonescimab combined with chemotherapy produced strong tumor responses before surgery; monotherapy also showed meaningful activity.
• All patients who underwent surgery achieved complete tumor removal with clear margins.
• The safety profile was manageable, with no surgeries canceled because of treatment-related adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611052127PR_NEWS_USPR_____CN90962) on November 06, 2026, and is solely responsible for the information contained therein.